• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

High-efficacy MAbs in MS: an update

November 25, 2015
Recommend to a Colleague print
 

ECTRIMS highlights

Efficacy results
Monitoring and safety issues
Commentary by Dr. Paul S. Giacomini, Associate Director, MS Clinic, Montreal Neurological Hospital and Institute, Assistant Professor, Department of Neurology and Neurosurgery, McGill University

It takes 30 seconds
or login using your email address

Please enter the email address that you registered the newsletter with

TOPICS: ECTRIMS 2015, MS
Recommend to a Colleague

Related Posts

  • Early, effective MS treatment revisited
    April 8, 2021
  • ACTRIMS FORUM 2021 – Highlights
    March 2, 2021
  • ACTRIMS FORUM 2021 – Highlights
    March 1, 2021
  • COVID-19 vaccines and Multiple sclerosis – update
    February 26, 2021
  • COVID-19 vaccines and Multiple sclerosis
    February 11, 2021
Go back to home page

Browse by Topic

MS (275)
AD (81)
PD (77)
PREVIOUS CONGRESSES (37)
DEPRESSION (36)
COVID-19 (27)
MIGRAINE (26)
SCHIZOPHRENIA (25)
STROKE (22)
EPILEPSY (21)
ECTRIMS 2015 (13)
AAN 2015 (11)
ECTRIMS 2014 (10)
DEMENTIA (10)
ECTRIMS 2018 (10)
ECTRIMS 2019 (10)
ECTRIMS 2013 (9)
AAN 2014 (9)
MS SEQUENCING (9)
AAN 2013 (9)
PSYCHIATRY (8)
ECTRIMS 2017 (7)
AAN 2019 (7)
ACTRIMS-ECTRIMS 2020 (7)
ECTRIMS 2016 (6)
CHARCOT 2013 (6)
CCSVI (5)
BIPOLAR (5)
ANXIETY (5)
NeuroSound (4)
EAN 2015 (4)
AAN 2017 (4)
BPD (4)
ENS 2013 (3)
PAIN (3)
AAN 2020 (3)
AAN 2018 (3)
Library (3)
SLEEP (2)
AAN 2016 (2)
NEW DRUGS (2)
APA 2014 (2)
SPECIAL REPORT (2)
EAN 2020 (2)
ADDICTION (1)
LUMBAR PUNCTURE (1)
CONCUSSION (1)
CIDP (1)
Dravet syndrome (1)
hATTR (1)
ALS (1)
SEIZURE (1)
INSOMNIA (1)
WEST NILE (1)
LGS (1)
APA 2016 (1)
EAN 2016 (1)
TSC (1)
GUIDELINES (1)
EAN 2019 (1)
ECTRIMS 2020 (0)
View all Topics

Popular Posts

  • How long does COVID immunity last? posted on April 6, 2021
  • Early, effective MS treatment revisited posted on April 8, 2021
  • AstraZeneca COVID-19 vaccine – the confusion continues posted on March 30, 2021
Copyright 2021 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions